CD36 and metabolic dysfunction-associated steatotic liver disease: In 2022, D’Espessailes A. et al., showed that Tocopherols (TF) supplementation in HFD-fed mice was able to modulate retinol metabolism, involved in the development of non-alcoholic fatty liver disease (NAFLD) through the reduction of the presence of lipid vesicles and total lipid content and the downregulation of the expression of hepatic retinaldehyde dehydrogenases such as RALDH1, RALDH3, SREBP-1c, and CD36 [44].